BACKGROUND AND AIMS: The serum trough level of adalimumab (ADA) associated with mucosal healing (MH) remains unclear. Our objective was to determine the association between ADA trough levels and the endoscopic activity in Crohn's disease. MATERIALS AND METHODS: This was a cross-sectional study including 42 patients with Crohn's disease. Endoscopic activity was assessed using the modified Rutgeerts scoring system. The primary outcome was mucosal healing, and the secondary outcomes were serum levels of C-reactive protein and albumin. RESULTS: Endoscopic disease activity negatively correlated with serum ADA trough levels (Spearman's rank correlation coefficient (ρ) = -0.42, P < 0.01). MH was achieved in 14 of 42 patients (33.3%). Serum ADA trough levels were significantly higher in the MH group than in the no-MH group (ADA mean trough level, 11.7 vs 7.5 µg/mL). The proportion of patients with ADA as the first biologic was significantly higher in the MH group than in the no-MH group (85.7% vs 53.5%, P = 0.04). The ADA trough levels that were best associated with normal C-reactive protein and albumin levels were 5.57 µg/mL (odds ratio [OR] 16.0, specificity 0.80) and 6.95 µg/mL (OR 9.2, specificity 0.81), respectively. The ADA trough level that was best associated with MH was 7.9 µg/mL (OR 13.5, specificity 0.86). The endoscopic disease activity was significantly higher in the patients with ADA as the second biologic as compared with those with ADA as the first biologic (P < 0.05). CONCLUSION: Mucosal healing requires higher ADA trough levels, compared with those required to normalization of routine clinical markers.
BACKGROUND AND AIMS: The serum trough level of adalimumab (ADA) associated with mucosal healing (MH) remains unclear. Our objective was to determine the association between ADA trough levels and the endoscopic activity in Crohn's disease. MATERIALS AND METHODS: This was a cross-sectional study including 42 patients with Crohn's disease. Endoscopic activity was assessed using the modified Rutgeerts scoring system. The primary outcome was mucosal healing, and the secondary outcomes were serum levels of C-reactive protein and albumin. RESULTS: Endoscopic disease activity negatively correlated with serum ADA trough levels (Spearman's rank correlation coefficient (ρ) = -0.42, P < 0.01). MH was achieved in 14 of 42 patients (33.3%). Serum ADA trough levels were significantly higher in the MH group than in the no-MH group (ADA mean trough level, 11.7 vs 7.5 µg/mL). The proportion of patients with ADA as the first biologic was significantly higher in the MH group than in the no-MH group (85.7% vs 53.5%, P = 0.04). The ADA trough levels that were best associated with normal C-reactive protein and albumin levels were 5.57 µg/mL (odds ratio [OR] 16.0, specificity 0.80) and 6.95 µg/mL (OR 9.2, specificity 0.81), respectively. The ADA trough level that was best associated with MH was 7.9 µg/mL (OR 13.5, specificity 0.86). The endoscopic disease activity was significantly higher in the patients with ADA as the second biologic as compared with those with ADA as the first biologic (P < 0.05). CONCLUSION: Mucosal healing requires higher ADA trough levels, compared with those required to normalization of routine clinical markers.
Authors: Konstantinos Papamichael; Adam S Cheifetz; Gil Y Melmed; Peter M Irving; Niels Vande Casteele; Patricia L Kozuch; Laura E Raffals; Leonard Baidoo; Brian Bressler; Shane M Devlin; Jennifer Jones; Gilaad G Kaplan; Miles P Sparrow; Fernando S Velayos; Thomas Ullman; Corey A Siegel Journal: Clin Gastroenterol Hepatol Date: 2019-03-27 Impact factor: 11.382
Authors: María Chaparro; Manuel Barreiro-de Acosta; Ana Echarri; Rosendo Almendros; Jesús Barrio; Jordina Llao; Fernando Gomollón; Maribel Vera; José Luis Cabriada; Jordi Guardiola; Iván Guerra; Belén Beltrán; Oscar Roncero; David Busquets; Carlos Taxonera; Xavier Calvet; Rocío Ferreiro-Iglesias; Virginia Ollero Pena; David Bernardo; María G Donday; Ana Garre; Ana Godino; Ana Díaz; Javier P Gisbert Journal: Dig Dis Sci Date: 2018-11-13 Impact factor: 3.199
Authors: Konstantinos Papamichael; Anna Juncadella; Danny Wong; Shana Rakowsky; Lindsey A Sattler; James P Campbell; Byron P Vaughn; Adam S Cheifetz Journal: J Crohns Colitis Date: 2019-08-14 Impact factor: 9.071
Authors: Cátia Rocha; Joana Afonso; Paula Lago; Bruno Arroja; Ana I Vieira; Claudia C Dias; Fernando Magro Journal: Therap Adv Gastroenterol Date: 2019-02-27 Impact factor: 4.409
Authors: Karoline Freeman; Sian Taylor-Phillips; Martin Connock; Rachel Court; Alexander Tsertsvadze; Deepson Shyangdan; Peter Auguste; Hema Mistry; Ramesh Arasaradnam; Paul Sutcliffe; Aileen Clarke Journal: BMJ Open Date: 2017-07-02 Impact factor: 2.692
Authors: Arne Carlsen; Roald Omdal; Lars Karlsen; Jan Terje Kvaløy; Lars Aabakken; Øyvind Steinsbø; Nils Bolstad; David Warren; Knut Erik Aslaksen Lundin; Tore Grimstad Journal: JGH Open Date: 2019-10-06